The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|April 11, 2022
Rheumatoid Arthritis Quiz: Effectiveness of COVID-19 Vaccines in Patients With RA
Author(s)Ingrid Torjesen
At the outset of the COVID-19 pandemic, there were concerns that patients with rheumatoid arthritis would be more vulnerable due to their condition and its treatment. What impact has the availability of vaccines against COVID-19 had on the vulnerability of patients with rheumatoid arthritis? Test your knowledge with this quiz.
Advertisement
What changes to disease activity can RA patients expect immediately post vaccination?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement